Lucid Diagnostics (LUCD) vs Sensus Healthcare (SRTS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Sensus Healthcare (SRTS) has outperformed Lucid Diagnostics (LUCD) over the past year, losing 43.8% versus a loss of 64.7%. Over five years, SRTS leads with a -63.5% price change compared with -95.6% for LUCD. Lucid Diagnostics is the larger company by market cap ($72.6 million vs $37.2 million), about 2.0 times the size.
Sensus Healthcare converts more of its revenue into profit, with a net margin of -28.1% versus -1232.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LUCD | SRTS |
|---|---|---|
| Share price | $0.3727 | $2.26 |
| Market cap | $72.57M | $37.20M |
| 1-day change | -3.52% | -4.24% |
| YTD return | -65.81% | -43.22% |
| 1-year return | -64.67% | -43.78% |
| 5-year return | -95.58% | -63.55% |
| EPS (TTM) | $-0.36 | $-0.97 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.71M | $27.48M |
| Revenue growth (YoY) | +8.28% | -34.26% |
| Net income (latest FY) | $-58.01M | $-7.72M |
| Gross margin | -41.73% | 43.18% |
| Operating margin | -1054.82% | -37.50% |
| Net margin | -1232.68% | -28.09% |
| 52-week high | $1.63 | $5.49 |
| 52-week low | $0.303 | $2.14 |
| Distance from 52-week high | -77.12% | -58.83% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +973.25% | +138.05% |
| Average volume | 5.15M | 208.74K |
| Shares outstanding | 194.71M | 16.46M |
| Employees | 82 | 60 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SRTS has outperformed LUCD by 20.9 percentage points over the past year.
- Sensus Healthcare is more profitable, keeping -28.1 cents of every revenue dollar as net income versus -1232.7 cents for Lucid Diagnostics.
- Lucid Diagnostics grew revenue faster in its latest fiscal year (+8.28% vs -34.26%).
About Lucid Diagnostics
LUCD stock →Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States.
Health Care · Medical/Dental Instruments · 82 employees
About Sensus Healthcare
SRTS stock →Sensus Healthcare, Inc. operates as a medical device company that manufactures and sells radiation therapy devices to healthcare providers worldwide.
Health Care · Medical/Dental Instruments · 60 employees
LUCD vs SRTS FAQ
Which is bigger, Lucid Diagnostics or Sensus Healthcare?
Lucid Diagnostics (LUCD) is larger, with a market capitalization of $72.57M compared with $37.20M for Sensus Healthcare (SRTS).
Which stock has performed better over the past year, LUCD or SRTS?
SRTS returned -43.78% over the past 12 months, compared with -64.67% for LUCD (price return, excluding dividends). Past performance does not predict future results.
Are Lucid Diagnostics and Sensus Healthcare in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.